Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Goserelin
Drug ID BADD_D01038
Description Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
Indications and Usage Goserelin is indicated for: - Use in combination with flutamide for the management of locally confined carcinoma of the prostate - Palliative treatment of advanced carcinoma of the prostate - The management of endometriosis - Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding - Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women
Marketing Status approved
ATC Code L02AE03
DrugBank ID DB00014
KEGG ID D04405
MeSH ID D017273
PubChem ID 5311128
TTD Drug ID D00BCG
NDC Product Code 55463-0005; 70720-951; 70720-950
UNII 0F65R8P09N
Synonyms Goserelin | ICI-118630 | ICI 118630 | ICI118630 | Zoladex | Goserelin Acetate | Acetate, Goserelin
Chemical Information
Molecular Formula C59H84N18O14
CAS Registry Number 65807-02-5
SMILES CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C( CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C 6CCC(=O)N6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vaginal haemorrhage24.07.03.005; 21.08.01.0010.000901%
Vaginal infection11.01.10.002; 21.14.02.002--
Varicose vein24.10.04.001--Not Available
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.0130.000501%Not Available
Vomiting07.01.07.003--
Vulvovaginal dryness21.08.02.003--
Vulvovaginitis21.14.02.005; 11.01.10.003--Not Available
Weight increased13.15.01.006--
Sudden cardiac death08.04.01.008; 02.03.04.016--Not Available
General physical health deterioration08.01.03.0180.000834%Not Available
Bone density decreased13.16.01.001--Not Available
Pituitary haemorrhage05.03.04.005; 24.07.04.009; 17.08.01.0190.000334%Not Available
Abulia19.01.02.009; 17.02.05.0400.000334%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000334%Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.003--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Exercise tolerance decreased08.01.03.0360.000334%Not Available
Malignant neoplasm progression16.16.01.0050.014348%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Eye pruritus06.04.05.006--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.001301%Not Available
Nodule08.03.05.002--Not Available
Affect lability19.04.01.001--Not Available
Injection site discomfort12.07.03.019; 08.02.03.0180.003404%Not Available
Bone cancer metastatic16.29.02.001; 15.09.03.004--Not Available
Haemorrhage24.07.01.0020.001235%Not Available
Intra-abdominal haematoma07.12.02.005; 24.07.02.0340.000501%Not Available
Muscle mass15.05.03.018--Not Available
The 10th Page    First    Pre   10 11 12    Next   Last    Total 12 Pages